*March 2022*
This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked. Learn more here.
*March 2022*
This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked. Learn more here.





The EGFR Resisters is a global community of patients and caregivers impacted by EGFR-positive lung cancer. We’re here to share knowledge, offer support and collaborate to drive progress in research and care. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.
